Skip to main content

Table 2 Prediction models for the leiomyosarcoma cohort based on each type of splicing event

From: Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas

Risk score Model HR (95% CI) p-value ROC
Risk score (AA) COPA_8458_AA * (− 0.168) + DMTF1_80302_AA * 0.035 + SNRPN_29704_AA * 0.361 3.102 (1.635–5.886) 0.0005 0.745
Risk score (AD) IFT81_24411_AD * 0.053 + NFATC4_26993_AD * (− 0.073) + RMI2_34011_AD * (− 0.092) + TLE3_31418_AD * (− 0.05) 6.875 (3.363–14.06) < 0.0001 0.763
Risk score (AP) CD2BP2_36095_AP * 0.463 + HMGCL_1078_AP * 0.228 + PAIP1_71959_AP * (− 0.209) + RAB5B_22326_AP * (− 0.175) + VAT1_41179_AP * 0.256 2.783 (1.445–5.360) 0.0022 0.86
Risk score (AT) ABCA1_87106_AT * (− 0.429) + C12orf75_24135_AT * 3.806 + COA3_41129_AT * (− 0.334) + TMEM14B_75308_AT * 0.131 3.282 (1.743–6.180) 0.0002 0.751
Risk score (ES) EDEM1_63033_ES * (− 0.51) + GNB2L1_75087_ES * (− 0.55) + NSUN5_270163_ES * 0.295 + RAB11FIP3_32895_ES * (− 0.089) + ZMYND11_10590_ES * (− 0.264) 5.290 (2.704–10.35) < 0.0001 0.857
Risk score (RI) CASP1_18519_RI * (− 0.043) + CCDC107_86266_RI * 0.103 + GBA2_86290_RI * (− 0.047) + KLHL25_32357_RI * (− 1.282) + TKT_65298_RI * (− 0.076) 6.271 (3.195–12.31) < 0.0001 0.797
Risk score (merged) NFATC4_26993_AD * (− 0.153) + HMGCL_1078_AP * 0.321 + COA3_41129_AT * (− 0.471) + TMEM14B_75308_AT * 0.328 + EDEM1_63033_ES * (− 0.447) + NSUN5_270163_ES * 0.493 + ZMYND11_10590_ES * (− 0.339) 5.678 (2.946–10.94) < 0.0001 0.781